We Care About Rare Diseases
Providing Life-Changing Solutions for Rare Diseases
Rare diseases are often time-critical—especially in pediatrics. ACA Pharma helps bring established global therapies to patients across Greater China, Southeast Asia and other key global markets where access can lag. Recent focus areas have included metabolic, neurologic, and hematologic disorders, but we are not limited to these fields—we support rare disease programs across therapeutic areas, with a practical emphasis on getting treatment to real patients quickly and responsibly.
Urea Cycle Disorders & Hyperammonemia
Life-threatening ammonia spikes that can present in newborns and children, requiring rapid intervention to prevent irreversible neurological damage.
Metabolic · PediatricPhenylketonuria (PKU)
A genetic condition where the body cannot properly process phenylalanine. Early treatment is critical to prevent irreversible neurologic harm across all ages.
Genetic · MetabolicFabry Disease
An X-linked lysosomal storage disorder driven by α-galactosidase A deficiency, with progressive impact on kidneys, heart, and peripheral nerves.
Rare · LysosomalMultiple Sclerosis (MS)
An immune-mediated CNS disease that often impacts people in early adulthood, where timely access to disease-modifying therapy can significantly alter disease course. In China, multiple sclerosis is notable as the most common neurological disorder in young people, aside from trauma-induced disorders.
Neurology · ImmunologyCell Therapy & Hematology
Omisirge® (omidubicel-onlv) is an FDA-approved cell therapy indicated for severe aplastic anemia (adults & pediatric ≥6) and hematologic malignancies (adults & pediatric ≥12) planned for cord blood transplantation.
Cell Therapy · FDA-ApprovedHow we accelerate access (especially for pediatric orphan drugs)
We use a repeatable access playbook that starts with Macau Fast-Track, leveraging established FDA/EMA/MHRA dossiers to secure approval in as little as 30–90 days, then bridging into various Mainland Pilot Zones such as the Greater Bay Area or Hainan . For pediatric orphan therapies, we can also activate Group NPP hospital procurement—a national network of 44 leading pediatric centers—so hospitals can obtain site import permits and begin treating eligible patients without waiting for full Mainland registration.
We pair early access with structured real-world evidence generation (e.g., in Pilot Zones like the Greater Bay Area) to enable faster national filings. Timelines can be ~3–6 months for pediatric orphan drugs and ~6–12 months for other urgent/orphan medicines — versus conventional pathways that often run multi-year.
Support for other key global markets
Beyond Greater China, our second core focus is helping rare-disease innovators expand internationally—starting with Singapore and other reliance-ready markets across Southeast Asia, and extending into India, the Middle East (including GCC markets), and other priority jurisdictions. Where eligible, we leverage prior approvals from reference regulators (e.g., FDA/EMA/MHRA) via abridged/verification and joint-assessment pathways to reduce duplicative review and minimize the need for new local clinical programs—while maintaining PV/QA rigor and full country-by-country compliance.
Asia Market Entry Specialists
On-the-ground execution, broader reach
We support rare-disease programs across therapeutic areas, from early access to multi-country expansion beyond China
